Literature DB >> 1955517

Response of the parathyroid gland to infusion of human parathyroid hormone-(1-34) [PTH-(1-34)]: demonstration of suppression of endogenous secretion using immunoradiometric intact PTH-(1-84) assay.

F Cosman1, V Shen, B Herrington, R Lindsay.   

Abstract

Alterations in the sensitivity of the parathyroid gland to both stimulative and suppressive stimuli may be partially responsible for skeletal changes that occur with age, estrogen deficiency, osteoporosis, and estrogen treatment of osteoporosis. We sought to define the changes in intact PTH-(1-84) secretion in normal premenopausal and postmenopausal, osteoporotic and estrogen-treated osteoporotic women during the infusion of human (h) PTH-(1-34). hPTH-(1-34) was infused at 0.55 U/kg.h for 24 h, with serum sampling every 4 h. Serum was analyzed for calcium (ionized and total), hPTH-(1-34), and PTH-(1-84). Basal chemistries were no different among groups, except for serum phosphorus, which was highest in osteoporotic women (1.31 vs. 1.07 mmol/L in premenopausal; P less than 0.02), and hPTH-(1-34), which was slightly higher in normal postmenopausal women (19.31 vs. 13.24 ng/L in estrogen treated; P less than 0.02). No differences in PTH-(1-84) were found among groups. hPTH-(1-34) rose similarly in all patient groups, while the calcemic response was somewhat more sluggish in estrogen-treated women, although statistically significant differences were not found. PTH-(1-84) declined rapidly in all patient groups, although estrogen-treated women had a smaller maximal decrease in PTH-(1-84), and the slope of the decremental change in PTH-(1-84) was lower in estrogen-treated women than in osteoporotic or normal postmenopausal women. Untreated osteoporotic women had less suppression of PTH-(1-84) than normal postmenopausal women at every calcium level. Estrogen treatment decreases the calcemic effects of infused hPTH-(1-34) and at the same time reduces calcium-induced suppression of parathyroid secretion. It is possible that such changes in the set-point of the gland contribute to the alterations in bone turnover that result in osteoporosis and the mechanisms by which estrogen prevents bone loss.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1955517     DOI: 10.1210/jcem-73-6-1345

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  8 in total

Review 1.  Parathyroid hormone as an anabolic skeletal therapy.

Authors:  Mishaela R Rubin; John P Bilezikian
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  A 7-day continuous infusion of PTH or PTHrP suppresses bone formation and uncouples bone turnover.

Authors:  Mara J Horwitz; Mary Beth Tedesco; Susan M Sereika; Linda Prebehala; Caren M Gundberg; Bruce W Hollis; Alessandro Bisello; Adolfo Garcia-Ocaña; Raquel M Carneiro; Andrew F Stewart
Journal:  J Bone Miner Res       Date:  2011-09       Impact factor: 6.741

3.  (1-34) Parathyroid hormone infusion acutely lowers fibroblast growth factor 23 concentrations in adult volunteers.

Authors:  Orlando M Gutiérrez; Kelsey T Smith; Allison Barchi-Chung; Neha M Patel; Tamara Isakova; Myles Wolf
Journal:  Clin J Am Soc Nephrol       Date:  2012-01       Impact factor: 8.237

4.  Effect of an oral calcium load on urinary markers of collagen breakdown.

Authors:  A Rubinacci; P Divieti; R M Polo; M Zampino; G Resmini; R Tenni
Journal:  J Endocrinol Invest       Date:  1996-12       Impact factor: 4.256

Review 5.  Advances in Our Understanding of the Mechanism of Action of Drugs (including Traditional Chinese Medicines) for the Intervention and Treatment of Osteoporosis.

Authors:  Junjie Lu; Desheng Hu; Chen Ma; Bo Shuai
Journal:  Front Pharmacol       Date:  2022-06-14       Impact factor: 5.988

6.  Alteration of the circadian rhythm of intact parathyroid hormone and serum phosphate in women with established postmenopausal osteoporosis.

Authors:  W D Fraser; F C Logue; J P Christie; S J Gallacher; D Cameron; D S O'Reilly; G H Beastall; I T Boyle
Journal:  Osteoporos Int       Date:  1998       Impact factor: 5.071

7.  Once-Weekly Injection of Low-Dose Teriparatide (28.2 μg) Reduced the Risk of Vertebral Fracture in Patients with Primary Osteoporosis.

Authors:  Takuo Fujita; Masao Fukunaga; Akira Itabashi; Kiichiro Tsutani; Toshitaka Nakamura
Journal:  Calcif Tissue Int       Date:  2013-08-21       Impact factor: 4.333

8.  Continuous and intermittent exposure of neonatal rat calvarial cells to PTHrP (1-36) inhibits bone nodule mineralization in vitro by downregulating bone sialoprotein expression via the cAMP signaling pathway.

Authors:  Suzan A Kamel; John A Yee
Journal:  F1000Res       Date:  2013-03-05
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.